161 related articles for article (PubMed ID: 38401187)
1. Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8.
Wu T; Chen Y; You Q; Jiang Z; Chen X
Eur J Med Chem; 2024 Mar; 268():116271. PubMed ID: 38401187
[TBL] [Abstract][Full Text] [Related]
2. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
4. Recent progress and structural analyses of domain-selective BET inhibitors.
Divakaran A; Harki DA; Pomerantz WCK
Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
6. MiR-185 attenuates androgen receptor function in prostate cancer indirectly by targeting bromodomain containing 8 isoform 2, an androgen receptor co-activator.
Jiang CY; Ruan Y; Wang XH; Zhao W; Jiang Q; Jing YF; Han BM; Xia SJ; Zhao FJ
Mol Cell Endocrinol; 2016 May; 427():13-20. PubMed ID: 26940039
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain inhibitors and therapeutic applications.
Gajjela BK; Zhou MM
Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
[TBL] [Abstract][Full Text] [Related]
8. The Bromodomain Containing 8 (BRD8) transcriptional network in human lung epithelial cells.
Browne JA; NandyMazumdar M; Paranjapye A; Leir SH; Harris A
Mol Cell Endocrinol; 2021 Mar; 524():111169. PubMed ID: 33476703
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain-containing proteins in prostate cancer.
Urbanucci A; Mills IG
Mol Cell Endocrinol; 2018 Feb; 462(Pt A):31-40. PubMed ID: 28624514
[TBL] [Abstract][Full Text] [Related]
10. Targeting bromodomain-containing proteins: research advances of drug discovery.
Pan Z; Zhao Y; Wang X; Xie X; Liu M; Zhang K; Wang L; Bai D; Foster LJ; Shu R; He G
Mol Biomed; 2023 May; 4(1):13. PubMed ID: 37142850
[TBL] [Abstract][Full Text] [Related]
11. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain protein BRD8 regulates cell cycle progression in colorectal cancer cells through a TIP60-independent regulation of the pre-RC complex.
Yamaguchi K; Nakagawa S; Saku A; Isobe Y; Yamaguchi R; Sheridan P; Takane K; Ikenoue T; Zhu C; Miura M; Okawara Y; Nagatoishi S; Kozuka-Hata H; Oyama M; Aikou S; Ahiko Y; Shida D; Tsumoto K; Miyano S; Imoto S; Furukawa Y
iScience; 2023 Apr; 26(4):106563. PubMed ID: 37123243
[TBL] [Abstract][Full Text] [Related]
13. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
[TBL] [Abstract][Full Text] [Related]
14. BRD8, which is negatively regulated by miR-876-3p, promotes the proliferation and apoptosis resistance of hepatocellular carcinoma cells via KAT5.
Yu Z; Chen T; Mo H; Guo C; Liu Q
Arch Biochem Biophys; 2020 Oct; 693():108550. PubMed ID: 32860757
[TBL] [Abstract][Full Text] [Related]
15. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
17. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition.
Ali MM; Naz S; Ashraf S; Knapp S; Ul-Haq Z
Int J Biol Macromol; 2023 Mar; 230():123428. PubMed ID: 36709803
[TBL] [Abstract][Full Text] [Related]
19. Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
Humphreys PG; Anderson NA; Bamborough P; Baxter A; Chung CW; Cookson R; Craggs PD; Dalton T; Fournier JCL; Gordon LJ; Gray HF; Gray MW; Gregory R; Hirst DJ; Jamieson C; Jones KL; Kessedjian H; Lugo D; McGonagle G; Patel VK; Patten C; Poole DL; Prinjha RK; Ramirez-Molina C; Rioja I; Seal G; Stafford KAJ; Shah RR; Tape D; Theodoulou NH; Tomlinson L; Ukuser S; Wall ID; Wellaway N; White G
J Med Chem; 2022 Nov; 65(22):15174-15207. PubMed ID: 36378954
[TBL] [Abstract][Full Text] [Related]
20. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
